2seventy Bio, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Director Sarah JS Glickman reports the disposal of shares and stock options in 2seventy bio, Inc. following the completion of a merger with Bristol-Myers Squibb Company.
Casdin Capital, LLC reports the tendering of shares and conversion of stock options and restricted stock units following the merger of 2seventy bio, Inc. with a subsidiary of Bristol-Myers Squibb Company.
Form 4: 2seventy bio Director Leschly Reports Shares Disposition Following Bristol-Myers Squibb Merger
Director Nick Leschly reports disposition of shares and derivative securities of 2seventy bio, Inc. following the merger with Bristol-Myers Squibb.
Form 4: 2seventy bio CFO Victoria Eatwell Disposes of Shares and Options in Merger with Bristol-Myers Squibb
Victoria Eatwell, CFO of 2seventy bio, reports the disposal of shares and options following the merger with Bristol-Myers Squibb, where 2seventy bio became a wholly-owned subsidiary.
Jessica Snow, Chief Operating Officer of 2seventy bio, Inc., reports the disposition of common stock and stock options due to the merger with Bristol-Myers Squibb Company.
Director Wei Lin reports the disposal of common stock and stock options in 2seventy bio following the completion of a merger with Bristol-Myers Squibb, where shares were converted to cash at $5.00 per share.
Form 4: 2seventy bio Director Maus Reports Acquisition by Bristol-Myers Squibb, Shares Converted to Cash
Director Marcela V. Maus reports the disposition of shares and stock options in 2seventy bio, Inc. following the merger with Bristol-Myers Squibb, where shares were converted to cash at $5.00 per share.
Director Charles W. Newton reports the disposal of shares and stock options in 2seventy bio, Inc. following the merger with Bristol-Myers Squibb Company.
Form 4: 2seventy bio Director Denice Torres Reports Disposal of Shares in Merger with Bristol-Myers Squibb
Director Denice Torres reports the disposal of shares and stock options in 2seventy bio following the completion of a merger with Bristol-Myers Squibb, where shares were acquired for $5.00 each.
William Baird III, CEO of 2seventy bio, reports the disposal of shares and stock options due to the merger with Bristol-Myers Squibb, where shares were acquired for $5.00 each.
Jessica Snow, Chief Operating Officer of 2seventy bio, Inc., sold 2,298 shares of common stock on March 17, 2025, to cover tax withholding obligations related to vesting restricted stock units.
William Baird III, CEO of 2seventy bio, Inc., sold 5,092 shares of common stock on March 17, 2025, to cover tax withholding obligations related to vesting restricted stock units.
Victoria Eatwell, CFO of 2seventy bio, Inc., sold 2,592 shares of common stock on March 17, 2025, to cover tax withholding obligations.
Kynam Global Healthcare Master Fund, LP reports the sale of 2seventy bio, Inc. shares at $4.93 per share.
Jessica Snow, Senior Vice President at 2seventy bio, files an amendment to a previous Form 4 to correct the number of shares sold on January 6, 2025.
Jessica Snow, a Senior Vice President at 2seventy bio, acquired 106,150 shares of common stock and 70,750 stock options on January 6, 2025.
2seventy bio's Chief Financial Officer, Victoria Eatwell, was granted 108,000 shares of restricted stock and options to purchase 72,000 shares of common stock.
2seventy bio's CEO, William Baird III, was granted 264,000 shares of restricted stock and options to purchase 176,000 shares on January 6, 2025.
Form 4: 2seventy bio Executive Jessica Snow Sells Shares to Cover Tax Obligations and Under 10b5-1 Plan
Jessica Snow, a Senior Vice President at 2seventy bio, sold shares of common stock to cover tax obligations and under a pre-arranged 10b5-1 trading plan.
Director Nick Leschly sold shares of 2seventy bio, Inc. to cover tax withholding obligations related to the vesting of restricted stock units.
Victoria Eatwell, CFO of 2seventy bio, sold shares of common stock on January 3rd and 6th, 2025, to cover tax withholding obligations related to vesting restricted stock units.
William D. Baird III, President and CEO of 2seventy bio, Inc., sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
Jessica Snow, a Senior Vice President at 2seventy bio, sold 2,287 shares of common stock at an average price of $3.2328 per share, under a pre-arranged 10b5-1 trading plan.
Marcela V. Maus, a director at 2seventy bio, sold 3,900 shares of common stock at an average price of $3.3801 per share on November 18, 2024.
Jessica Snow, Senior Vice President at 2seventy bio, sold 679 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
Victoria Eatwell, CFO of 2seventy bio, sold 1,230 shares of common stock to cover tax withholding obligations.
Jessica Snow, Senior Vice President at 2seventy bio, Inc., sold 7,816 shares of common stock at a weighted average price of $4.3194 on August 14, 2024.
Victoria Eatwell, CFO of 2seventy bio, Inc., sold shares of common stock on August 5, 2024, to cover tax withholding obligations related to vesting restricted stock units.
William D. Baird III, President and CEO of 2seventy bio, Inc., reports acquiring and disposing of common stock on July 1, 2024.
Jessica Snow, a Senior Vice President at 2seventy bio, sold 14 shares of common stock at an average price of $4.0178 to cover tax withholding obligations related to vesting restricted stock units.